Welcome to our dedicated page for Moderna SEC filings (Ticker: MRNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Moderna, Inc. filings document the regulatory, financial and governance record of a commercial-stage mRNA biotechnology company. Form 8-K reports cover operating results, Regulation FD updates, FDA communications for investigational vaccine submissions, material agreements, patent-litigation settlements and financing arrangements tied to the company's vaccine and therapeutic portfolio.
Proxy and annual-meeting filings disclose board elections, shareholder voting results, executive compensation and governance provisions, including bylaw amendments. The filings also record capital-structure matters such as credit facilities, risk and disclosure controls around pipeline development, and formal updates related to products including Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX.
Moderna, Inc. director Sandra Horning increased her direct common stock holdings through equity compensation, not open‑market trading. On April 30, 2026, 16,233 restricted stock units converted into 16,233 shares of common stock on a one-for-one basis when the award vested in full. Following this exercise-and-hold event, she directly holds 18,585 Moderna common shares. The filing shows no stock sales, gifts, or tax-withholding dispositions, indicating a routine vesting of previously granted RSUs rather than a market purchase or sale.
Moderna director David M. Rubenstein exercised restricted stock units to receive 8,116 shares of Common Stock. The RSUs converted into common stock on a one-for-one basis and vested in full on April 30, 2026.
Following this vesting and conversion, Rubenstein directly holds 9,643 shares of Moderna common stock. The filing shows no open-market purchases or sales, only the automatic conversion of a stock-based compensation award into shares.
Moderna, Inc. director Hussain Abbas reported an exercise of restricted stock units (RSUs) and a related share sale. On April 30, 2026, RSUs covering 16,233 shares converted into common stock on a one-for-one basis when they vested in full. On May 1, 2026, Abbas sold 5,682 common shares at an average price of $46.63 per share under a pre-arranged Rule 10b5-1 trading plan to generate cash to cover tax liabilities from the RSU vesting. After these transactions, he directly owned 12,066 Moderna common shares.
Moderna, Inc. director Elizabeth G. Nabel acquired common shares through an equity award vesting. On April 30, 2026, 16,233 restricted stock units converted into 16,233 shares of common stock on a one-for-one basis. These RSUs vested in full on that date.
After the conversion, Nabel directly owned 19,317 shares of Moderna common stock. The filing shows an exercise or conversion of a derivative security related to compensation, with no open-market purchase or sale reported in this transaction.
Moderna director Nader Francois increased his direct equity stake through RSU vesting, not open-market buying. On April 30, 2026, 12,174 restricted stock units converted into the same number of Moderna common shares on a one-for-one basis at an exercise price of $0.00 per share.
These RSUs vested in full on that date, reflecting compensation rather than a market trade. Following the conversion, Francois directly owns 32,781 shares of Moderna common stock.
Moderna director Elizabeth E. Tallett exercised restricted stock units into common shares. On April 30, 2026, 4,058 restricted stock units converted into 4,058 shares of Moderna common stock at an exercise price of $0.00 per share. Following this transaction, she directly holds 4,761 common shares. The restricted stock unit award vested in full on April 30, 2026, and the filing shows no remaining derivative position tied to this award.
Moderna reported a sharply wider net loss for Q1 2026 as a major legal settlement overshadowed strong vaccine revenue growth. Total revenue rose to $389 million from $108 million, driven by higher COVID vaccine sales, especially in Europe, and increased stand-ready manufacturing revenue.
Net loss deepened to $1.343 billion, or $(3.40) per share, mainly because cost of sales jumped to $955 million, including about $878 million of royalty and settlement-related expenses tied to resolving global litigation with Arbutus and Genevant. R&D and SG&A both declined year over year as the company tightened spending.
Moderna ended the quarter with $7.456 billion in cash, cash equivalents and investments and a long-term term loan of $600 million. It also signed a $50 million propionic acidemia collaboration with Recordati, continued to receive influenza program funding from Blackstone, and secured European Commission approval for its mCOMBRIAX flu–COVID combination vaccine.
Moderna, Inc. reported first quarter 2026 revenue of $389 million, up from $108 million a year earlier, with $311 million from international markets as COVID vaccine sales rose under long-term government partnerships.
The company posted a GAAP net loss of $1.343 billion, or $(3.40) per share, largely due to a $0.9 billion non-recurring litigation settlement charge recorded in cost of sales. Research and development expenses fell 24% to $649 million and selling, general and administrative expenses decreased 18% to $173 million, reflecting wind-down of large respiratory programs and cost discipline. Cash, cash equivalents and investments totaled $7.5 billion as of March 31, 2026, and Moderna is targeting up to 10% revenue growth for 2026 while projecting year-end cash and investments of $4.5 to $5.0 billion.